Physician profile
Anna Plemmons
NPI 1295387223
$2,615.44
in general payments reported to CMS, 2019-2025
17 companies · $814 in 2025
The $814 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $175 · 2023: $711 · 2024: $916 · 2025: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,238 · Education: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,237.85 |
| Education | $202.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $566.92 | 2022-2025 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $507.29 | 2022-2025 | Fasenra, Tezspire, Breztri |
| Insmed, INC. | $267.50 | 2022-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.53 | 2022-2025 | Ofev |
| Merck Sharp & Dohme LLC | $235.52 | 2022-2025 | Zerbaxa, Recarbrio, Winrevair |
| Takeda Pharmaceuticals U.S.A., INC. | $168.61 | 2023-2025 | Glassia |
| Olympus America INC. | $137.06 | 2024 | Spiration Valve System |
| Janssen Pharmaceuticals, INC | $98.23 | 2022-2024 | Xarelto |
| Glaxosmithkline, LLC. | $80.34 | 2023-2025 | Nucala |
| Alexion Pharmaceuticals, INC. | $60.14 | 2023-2025 | Ultomiris, Soliris |
| Viatris Specialty LLC | $48.26 | 2025 | Yupelri |
| La Jolla Pharmaceutical Company | $41.87 | 2025 | Giapreza |
| Bayer Healthcare Pharmaceuticals INC. | $41.69 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $40.38 | 2024 | Dupixent |
| Grifols USA, LLC | $39.36 | 2024-2025 | Prolastin-C Liquid, Xembify |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $16.66 | 2025 | |
| Mallinckrodt Hospital Products INC. | $16.08 | 2024 | Terlivaz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Plemmons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.